Medicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.
Prescription Drugs
Posted inCost of Care
Medicare Releases Details of Major Drug Price Reform
Medicare’s historic plan to slow prescription drug spending is taking shape.
Posted inCost of Care
The End of Humira’s $200 Billion Drug Monopoly
What will happen when the best selling drug ever finally faces direct competition?
Posted inPublic Health
Three Health Policy Stories to Watch in 2023
In 2023, states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare will begin to flex its new power to negotiate drug prices.
Posted inMental Health
Local Officials Grapple With How to Spend Billions in Opioid Settlement Dollars
More than $50 billion in opioid settlement dollars from drugmakers, distributors and pharmacies are starting to flow to state and local governments.
Posted inPublic Health
Drugmakers and Patient Assistance Programs: Tricks or Treats?
Stacie Dusetzina shares new research that examines the link between drug companies’ charity donations and their business incentives.
Posted inInsurance
Medicare’s Prescription Drug Plan Makeover
An overhaul of Medicare’s prescription drug benefit will lower costs for seniors while changing incentives for insurers and drugmakers.
Posted inCost of Care
The Race to Prepare for Medicare’s New Drug Pricing Powers
Congress gave Medicare historic new powers to lower drug prices, but lawsuits, loopholes and opposition from the drug industry could undermine them.
Posted inCost of Care
Dems’ New Drug Pricing Deal: What You Need to Know
Stacie Dusetzina shares key takeaways from the drug pricing provisions of the new Inflation Reduction Act.
Posted inHealth Equity
Good Intentions Gone Awry
Why has a little-known program designed to help hospitals and clinics that serve low-income people become so controversial?